| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
1 Department of Surgery, University of New South Wales, St. George Hospital, Sydney, New South Wales 2217, Australia
2 Department of Radiology, University of New South Wales, St. George Hospital, Sydney, New South Wales 2217, Australia
Correspondence: Address correspondence and reprint requests to: David L. Morris, MD, PhD, E-mail: david.morris{at}unsw.edu.au
Background: This study critically evaluated the local and overall treatment failure rates after percutaneous radiofrequency ablation (RFA) of pulmonary metastases from colorectal carcinoma.
Methods: Fifty-five nonsurgical candidates underwent RFA of colorectal pulmonary metastases. The primary end points of this study were local progression-free survival (PFS) and overall PFS. Univariate and multivariate analyses were performed to identify significant prognostic parameters for local and overall PFS.
Results: The local recurrence rate was 38%. For local PFS, univariate analysis demonstrated that the largest size of lung metastasis, the location of lung metastases, the post-RFA carcinoembryonic antigen level at 1 month, and the post-RFA carcinoembryonic antigen level at 3 months were significant prognostic indicators. In multivariate analysis, a largest size of lung metastasis of >3 cm and a post-RFA carcinoembryonic antigen level of >5 ng/mL at 1 month were independently associated with a reduced local PFS. The overall recurrence rate was 66%. For overall PFS, univariate analysis demonstrated that sex and the largest size of lung metastasis were significant prognostic indicators. In multivariate analysis, a largest size of lung metastasis of >3 cm was independently associated with a reduced overall PFS.
Conclusions: RFA of colorectal pulmonary metastases may have a useful role in local disease control for nonsurgical candidates, but its efficacy in patients with a lung metastasis of >3 cm is limited.
Key Words: Radiofrequency ablation Pulmonary metastases Colorectal carcinoma
This article has been cited by other articles:
![]() |
A. Pennathur, G. Abbas, I. Qureshi, M. J. Schuchert, Y. Wang, S. Gilbert, R. J. Landreneau, and J. D. Luketich Radiofrequency Ablation for the Treatment of Pulmonary Metastases Ann. Thorac. Surg., April 1, 2009; 87(4): 1030 - 1039. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J.A. Haasbeek, S. Senan, E. F. Smit, M. A. Paul, B. J. Slotman, and F. J. Lagerwaard Critical Review of Nonsurgical Treatment Options for Stage I Non-Small Cell Lung Cancer Oncologist, March 1, 2008; 13(3): 309 - 319. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. A. Haasbeek, S. Senan, E. F. Smit, F. J. Lagerwaard, D. E. Dupuy, C. J. Simon, T. A. DiPetrillo, T. Ng, and W. W. Mayo-Smith CT-guided Pulmonary Radiofrequency Ablation Radiology, January 1, 2008; 246(1): 334 - 335. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |